All News
Quiz Talk (5.22.2026)
Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
Read Article
Review of Toll-like Receptor Research
EurekAlert!
A new review on Toll-like receptors (TLRs) systematically summarizes forty years of discoveries in the TLR field, from the initial identification of Toll in Drosophila embryonic development to the current understanding of
Read Article
Follow the Money (4.23.2026)
Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week.
Read Article
Still's Disease Update
Arthritis Research & Therapy has published an overarching review of Still's disease - claiming it to be a single acquired and complex autoinflammatory disease in which both pediatric and adult forms share core pathogenic mechanisms, genetic associations and clinical presentations, with minor differences between children and adults who are afflicted.
Read Article
Top Four and More (4.10.2026)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week - including his top four favorite subjects.
Read Article
Review of Ruxolitinib in 7 pts w/ refractory systemic JIA complicated by macrophage activation (MAS) (ages 1.6-11 yrs; 3M: 4F). 5 achieved complete remission; 2 partial remission. 2 relapsed w/ GC tapering (remission after adding canakinumab). No deaths https://t.co/j4Cm3UYB9c https://t.co/pKoDwpSKII
Dr. John Cush RheumNow ( View Tweet)
Review of Ruxolitinib in 7 pts w/ refractory systemic JIA complicated by macrophage activation (MAS) (ages 1.6-11 yrs; 3M: 4F). 5 achieved complete remission; 2 partial remission. 2 relapsed w/ GC tapering (remission after adding canakinumab). No deaths https://t.co/j4Cm3UYB9c https://t.co/YIupsBank5
Dr. John Cush RheumNow ( View Tweet)
FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/qqPsjhUClP https://t.co/lCZNoTh9fv
Dr. John Cush RheumNow ( View Tweet)
10yr retrosp. study of 110 Still’s dz pts. MAS occurred in 37% (1/2 @onset; assoc w/ serositis) and ILD observed in 82% (also assoc w/ MAS, polycyclic course) https://t.co/SNa0KiWfgY https://t.co/xbpCuHdJka
Dr. John Cush RheumNow ( View Tweet)
APR: Still's Disease
Companion slide deck for the Advanced Practice Rheum: Still's Disease and Fever video, featuring Dr. Jack Cush.
https://t.co/wsUP2zEulC https://t.co/AWSNt9Uzlg
Dr. John Cush RheumNow ( View Tweet)
In Still's disease, what is the primary life-threatening complication clinicians must monitor for? If you think you know the answer, prove it in this week's RheumIQ quiz at https://t.co/KVK8J2iaFQ https://t.co/O62ZpIciWW
Dr. John Cush RheumNow ( View Tweet)
Mevalonate kinase deficiency (AKA hyper-IgD syndr-HIDS) is a rare autosomal recessive autoinflammatory dz of the MVK gene w/ exaggerated innate immunity & incr IL-1β production. Usually Dx in kids, milder forms of periodic fever syndrome have been seen in adults. https://t.co/0hAIz4JgY3
Dr. John Cush RheumNow ( View Tweet)
Still's Disease Update
Arthritis Research & Therapy has published an overarching review of Still's disease, claiming it is a single acquired, complex autoinflammatory disease in which both pediatric and adult forms share core pathogenic mechanisms, genetic associations, and https://t.co/8ctddvIq7k
Dr. John Cush RheumNow ( View Tweet)
VEXAS Syndrome - A Review
Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.
https://t.co/Nik0TJm6Qu https://t.co/WS35PRnbBv
Dr. John Cush RheumNow ( View Tweet)
Machine learning predicts macrophage activation syndrome in adult Still's disease - 312 AOSD - XGBoost model had 5 predictors: ferritin, splenomegaly, Plt#, cholesterol, & ESR (AUC 0.839, sensit 0.824, specificity 0.710. https://t.co/QrogaCYPCT https://t.co/Z6WgCnFTfx
Dr. John Cush RheumNow ( View Tweet)
19 yr old male is Dx w/ Stills Dz (Fever 104F, pleuritis, organomegaly, WBC 24k, ESR 98, CRP 11 mg/L) - what drug do you prescribe first?
Dr. John Cush RheumNow ( View Tweet)
19 yr old male is Dx w/ Stills Dz (Fever 104F, pleuritis, organomegaly, WBC 24k, ESR 98, CRP 11 mg/L) - what drug do you prescribe first?
Dr. John Cush RheumNow ( View Tweet)
A multi-center, retrospective chart review of 82 Still's disease pts (63% female; mean Dx age 6.4 ± 4 yrs; F/U ~2.8 yrs). When analyzing Dz course, 34% were monophasic, 46% polyphasic (higher-than-expected), 19.5% persistent Dz. non-monophasic predicted by active 3 mos from Dx https://t.co/V7OxwEI4it
Dr. John Cush RheumNow ( View Tweet)
Disease activity defined in adult-onset Still's dz. Criteria developed using Italian cohort 187 & 41 from CONSIDER (canakinumab) trial. Active AOSD based on 5 criteria: fever, plus 1: skin rash, arthritis, pt global>2 cm, CRP > 10 mg/L; or any 3 without fever (AUC 0.93, 0.85, https://t.co/J94pkQqZFP
Dr. John Cush RheumNow ( View Tweet)
